Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
The absence of 25-hydroxyvitamin D3-1α-hydroxylase potentiates the suppression of EAE in mice by ultraviolet light.
Will the real multiple sclerosis please stand up?
Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study
Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets.
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) in the Italian population.
Dimethyl fumarate regulates histone deacetylase expression in astrocytes.
Stride time variability as a marker for higher level of gait control in multiple sclerosis: its association with fear of falling.
Geography in multiple sclerosis.
Daclizumab in multiple sclerosis: a high-yield extension study.
Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.
Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy?
Use of rituximab in multiple sclerosis: current progress and future perspectives.
Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.
Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Mechanism of action for leflunomide in rheumatoid arthritis.
The cell biology of CNS myelination.
Improvements in cognition, quality of life, and physical performance with clinical Pilates in multiple sclerosis: a randomized controlled trial.
LINGO-1, A TRANSMEMBRANE SIGNALING PROTEIN, INHIBITS OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION THROUGH INTERCELLULAR SELF-INTERACTIONS.
Neurological involvement in Primary Sjögren Syndrome.
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain.
Pages
« first
‹ previous
…
43
44
45
46
47
48
49
50
51
…
next ›
last »